AllSci News
Triveni Bio secures USD 65 million to expand first-in-class bispecific antibody into atopic dermatitis
Watertown, Massachusetts-based Triveni Bio Inc., a clinical-stage biotechnology company developing antibody therapies for immunological and inflammatory...
Verastem's RAF/MEK-FAK strategy shows encouraging survival signal in pancreatic cancer
Updated data from the RAMP 205 trial show that avutometinib plus defactinib, layered on top of gemcitabine and nab-paclitaxel, produced a 52% confirmed...
NIDA renews support for Northeastern cannabinoid drug discovery program
Northeastern University has received a USD 1.43 million NIDA P01 program project renewal to advance structure-guided drug discovery targeting CB1 and CB2...
Rutgers researchers explore PARP1 inhibition as strategy against chemotherapy-related cognitive impairment
Rutgers Biomedical and Health Sciences has received a USD 1.78 million National Cancer Institute R01 award to identify biomarkers and evaluate therapeutic...
ScinnoHub launches Phase I study of RET inhibitor aimed at post-Retevmo/Gavreto resistance
China-based ScinnoHub Pharmaceutical Co., Ltd. has initiated a first-in-human Phase I trial of SNH-118110, an oral small-molecule RET inhibitor, in patients...
NMD Pharma reports functional gains for CIC-1 inhibitor in CMT despite Phase IIa endpoint miss
Functional improvements in hand grip strength and composite motor measures in Charcot-Marie-Tooth disease patients — sustained a week after treatment...
Akeso revives CD47 strategy in AML after strong Phase II showing for ligufalimab
A randomized, placebo-controlled Phase II trial of ligufalimab, a CD47-targeting antibody, has reported survival data in treatment-naïve AML that positions...
Bayer completes USD 2.45b purchase of Perfuse for first-in-class endothelin antagonist
Bayer has completed its acquisition of Perfuse Therapeutics, gaining full global rights to PER-001, a first-in-class sustained-release endothelin receptor...
Zydus expands US oncology footprint with USD 166 million Assertio acquisition
India-based Zydus Lifesciences (NSE: ZYDUSLIFE) completed its acquisition of Lake Forest, Illinois-based Assertio Holdings, Inc. (Nasdaq: ASRT) on June 16,...
Edgewise's EDG-7500 opens potential path in nonobstructive HCM beyond myosin inhibitors
EDG-7500 hypertrophic cardiomyopathy data from Boulder, Colorado-based Edgewise Therapeutics (Nasdaq: EWTX) are pointing toward a mechanistically distinct...
Trellis opens inhaled antibody route to tackle lung infections resistant to systemic therapy
Redwood City, California-based Trellis Bioscience LLC is advancing a first-in-human trial of inhaled TRL1068, a human monoclonal antibody designed to...
GSK advances passive malaria immunization with first-in-human monoclonal antibody trial
GlaxoSmithKline (NYSE: GSK) has initiated a first-in-human dose-escalation trial of GSK4425689A, a monoclonal antibody (mAb) intended for the prevention of...
Ratio Therapeutics secures second source of actinium-225 to advance targeted alpha therapy pipeline
Lansing, Michigan-based Niowave, Inc. and Boston-based Ratio Therapeutics Inc. announced a supply agreement under which Niowave will provide actinium-225 (Ac-225) to support…
Innoviva expands antibiotic Xacduro into emerging markets with Dr. Reddy's partnership
Innoviva's only FDA-approved antibiotic for carbapenem-resistant Acinetobacter baumannii is heading to some of the world's most resistance-burdened hospital...
InnovStone enters crowded aldosterone synthase inhibitor race with oral SYH2072
InnovStone Therapeutics Advances SYH2072 into First-in-Human Testing as Aldosterone Synthase Inhibitor Field Grows More Competitive
The AllSci Brief
Systematic R&D and deal news. Daily.